Approval Number : National Drug Standard H20057988
Usage and dosage: The commonly used dosage of levofloxacin lactate oral formulations is 250 mg, 500mg, or 750mg, taken orally every 2 hours. (See instructions for details)
Detail
Approval Number : 国药准字H20083528
Levofloxacin is the levorotatory form of ofloxacin, and its antibacterial activity is approximately twice that of ofloxacin. It belongs to the third generation of fluoroquinolone antibacterial drugs, with wide distribution in tissues, long-lasting antibacterial effects, and high bioavailability. It is suitable for infections caused by Gram-negative bacteria, Gram-positive bacteria, and anaerobic bacteria in skin and soft tissue, respiratory system, digestive system, and urinary system.
Detail
Approval Number : 国药准字H20094204
1. A new generation of intravenous potassium phosphate supplement, potassium phosphate co-supplement, safe and efficient. 2. Essential electrolyte for diabetic patients. 3. Used for hypophosphatemia caused by certain diseases (cardiovascular diseases, respiratory diseases, liver diseases, kidney diseases, etc.). 4. The potassium ions in this product exist in the form of phosphate salts, which are closer to the blood environment of the human body. 5. Listed under the national medical insurance category B.
Detail
Approval Number : 国药准字H20057288
This product is rapidly and completely absorbed after oral administration (>95%). The bioavailability is approximately 50%. After absorption, it quickly enters extracellular tissues and can penetrate the blood-brain barrier and placental barrier. The protein binding rate is low, about 10%. The peak blood concentration is reached 1.5 hours after oral administration, and the duration of action is 1-2 hours. The decrease in blood pressure does not parallel the blood drug concentration, while the decrease in heart rate is linearly related to the blood drug concentration. The half-life is 3-5 hours and is not significantly altered in renal dysfunction. It undergoes hepatic metabolism and is excreted through the kidneys. The majority of excretion in urine is in the form of metabolites, with only a small amount (3%-10%) excreted unchanged.
Detail
Approval Number : 国药准字H20052313
The product is a mucolytic agent that can increase the secretion of respiratory mucous gland, reduce mucus gland secretion, and thereby reduce mucus viscosity. It can also promote the secretion of pulmonary surfactants, increase bronchial ciliary movement, and facilitate expectoration of sputum.
Detail
Approval Number : 国药准字H20065189 国药准字H20065190
Naloxone hydrochloride was synthesized in 1960 and is a derivative of hydroxy(dihydro)ketomorphine. Naloxone is an opioid receptor antagonist and was initially used to counteract opioid overdose. It has the specific effect of reversing respiratory depression and inducing awakening. It is a highly effective antidote for opioid overdose and a diagnostic drug for morphine and heroin dependence. Based on studies of the physiological effects of endogenous opioid-like substances, clinical researchers have not only used naloxone to antagonize respiratory depression caused by opioid drugs but have also conducted trials on stress-related diseases such as non-anesthetic drug overdose (ethanol, benzodiazepines), shock, cerebral infarction, and neonatal asphyxia syndrome, achieving good therapeutic results and generating great interest among doctors both domestically and internationally. In recent years, clinicians at home and abroad have also used it for the treatment of acute alcohol and sedative poisoning, hepatic encephalopathy, cerebral infarction, post-asphyxial ischemic encephalopathy in neonates, severe heatstroke, acute and chronic respiratory failure, and various critical conditions, with good results.
Detail
Approval Number : 国药准字H20080551 国药准字H20080629 国药准字H20080552
Naloxone hydrochloride, synthesized in 1960, is a derivative of hydroxy (di)morphinone. Naloxone is an opioid receptor antagonist primarily used to counteract opioid overdose. It has respiratory stimulant and awakening effects, making it an effective antidote for opioid overdose and a diagnostic tool for opioid and heroin dependence. Building on the research of endogenous opioid-like substances\' physiological effects, clinical practitioners have found success in using naloxone not only to reverse opioid-induced respiratory depression but also in the treatment of non-anesthetic drug overdose (such as alcohol and benzodiazepines), shock, cerebral infarction, neonatal asphyxia syndrome, and other stress-related disorders. This has garnered significant interest among medical professionals both domestically and internationally. In recent years, clinicians have also utilized naloxone in the treatment of acute alcohol and sedative poisoning, hepatic encephalopathy, cerebral infarction, post-asphyxial ischemic encephalopathy in neonates, severe heatstroke, acute and chronic respiratory failure, as well as various critical shock conditions, all with positive outcomes.
Detail
Approval Number : 国药准字H20055299 国药准字H20055300
This product is a structural analog of deoxyguanosine and can inhibit the replication of herpes viruses. Its mechanism of action involves ganciclovir being initially phosphorylated by a protein kinase homolog encoded by the UL97 gene of cytomegalovirus (CMV) to form a monophosphate salt. It is further phosphorylated into diphosphate and triphosphate forms by cellular kinases. In CMV-infected cells, the concentration of triphosphate is 100 times higher than that in uninfected cells, indicating that the product is preferentially phosphorylated in infected cells. Once ganciclovir is in the triphosphate form, it can persist in CMV-infected cells for several days. The triphosphate form of ganciclovir inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and incorporating into the DNA of both the virus and host cells, leading to termination of viral DNA elongation. Ganciclovir exhibits stronger inhibition on viral DNA polymerase compared to host polymerase.
Detail